SOURCE: SomaLogic

October 30, 2014 12:18 ET

SomaLogic Announces New "Fit-For-Purpose" SOMAmer® Discovery Service

Launch Includes a Contest to Win a Free SOMAmer Reagent Discovery Package

BOULDER, CO--(Marketwired - October 30, 2014) - SomaLogic announced today the launch of a new proteomics service offering aimed at providing its breakthrough protein-binding SOMAmer® reagents to the scientific community based on their specific needs in wide variety of different research uses. The SOMAmer Discovery Service team at SomaLogic will work closely with SomaLogic customers to develop and license "fit-for-purpose" SOMAmer reagents that strongly bind the customers' proteins of interest, and function correctly in the particular assays they are performing with the reagents.

To celebrate the launch of this new service, SomaLogic is sponsoring the "SOMAmer Challenge," a contest in which participants can name specific proteins of interest for a chance to win a free SOMAmer Discovery Service package (see www.somamerchallenge.com for more information about the contest, and terms and conditions).

SOMAmer (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic's proteomics technology platform, are a new class of superior protein-binding reagents that combine the high specificity and affinity of monoclonal antibodies with the stability and lot-to-lot consistency of traditional aptamers. They have wide applicability in many current preclinical and clinical analytical assays, including quantitative high-content screening, targeted panels, flow cytometry, histochemistry, functional assays, and biophysical methods.

"We are delighted that we can now offer our SOMAmer Discovery Service to scientists looking for specific, dependable protein-binding molecules for their particular research needs," said Paul Menter, Vice President and General Manager of Life Science at SomaLogic. "We believe that this service fills a critical need for high affinity and robust binding reagents for many different laboratory applications."

Compared to other available proteomic technologies, SomaLogic's offerings provide researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SomaLogic's commercially available SOMAscan™ assay, which incorporates 1129 different SOMAmer reagents in the current version, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

About SomaLogic

SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colo. The company's mission is to use its proprietary modified aptamer-based proteomic technologies to develop a wide range of enhanced protein-analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of health care by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.

Attachment Available: http://www.marketwire.com/library/MwGo/2014/10/30/11G025066/SOMAmer_challenge-511790576650.pdf

Contact Information

  • EDITORIAL CONTACT: 
    Fintan R. Steele, Ph.D.
    fsteele@somalogic.com
    +1 720-214-3080 - P
    +1 617-816-9834 - C